Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA
作者:Adam Ametovski、Christa Macdonald、Jamie J. Manning、S. A. Syed Haneef、Marina Santiago、Lewis Martin、Eric Sparkes、Andrew Reckers、Roy R. Gerona、Mark Connor、Michelle Glass、Samuel D. Banister
DOI:10.1021/acschemneuro.0c00591
日期:2020.11.4
relatively greater affinity and potency of (S)-14–17 compared to (R)-14–17 analogues at CB1 highlighted an enantiomeric bias for this series of SCRAs. Molecular dynamics simulations provided a conformational basis for the observed differences in agonist potency at CB1 pending benzylic substitution.
合成大麻素受体激动剂(SCRA)代表了发展最快的一类新型精神活性物质(NPS)。尽管最近手性吲哚-3-羧酰胺SCRA的流行和效力,有关这些NPS对人CB1和CB2受体的对映体偏倚的药理学数据很少。制备了一系列衍生自(S)-和(R)-α-甲基苄基胺并具有1-烷基取代基变异特征的同手性吲哚-3-羧酰胺,对其进行了药理学评价,并将其与衍生自枯基和苄基胺的相关非手性同类物进行比较。竞争性结合测定表明,所有类似物均来自α-甲基苄胺的对映体(14 –17)显示CB1(K i = 47.9–813 nM)和CB2(K i = 47.9–347 nM)的亲和力处于相应苄基的中间值(10 – 13,CB1 K i = 550 nM到> 10μM ; CB2 ķ我= 61.7 nM至>10μM)和枯基衍生物(6 - 9,CB1 ķ我= 12.6-21.4纳米; CB2 ķ我= 2.95-24.5纳米)。在荧光